1 / 29

SELECTED GERIATRIC NEUROLOGIC DISEASE Module 1 Parkinson’s disease

SELECTED GERIATRIC NEUROLOGIC DISEASE Module 1 Parkinson’s disease. Bill Lyons, M.D. UNMC Geriatrics Asst. Professor wlyons@unmc.edu. OVERVIEW. Parkinson’s disease Other movement disorders Stroke and TIA. Objectives. Re: Parkinson’s disease, upon completion the learner will be able to;

minat
Télécharger la présentation

SELECTED GERIATRIC NEUROLOGIC DISEASE Module 1 Parkinson’s disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SELECTED GERIATRIC NEUROLOGIC DISEASEModule 1Parkinson’s disease Bill Lyons, M.D. UNMC Geriatrics Asst. Professor wlyons@unmc.edu

  2. OVERVIEW • Parkinson’s disease • Other movement disorders • Stroke and TIA

  3. Objectives Re: Parkinson’s disease, upon completion the learner will be able to; • List the diagnostic characteristics • Describe the key pathologic features • Describe evaluation and management • List the most common complications

  4. PARKINSON’S DISEASE • Prevalence increases with age (starts 40s-60s) • Seen in all ethnic groups, M:F about 1.5:1 • Second most common neurodegenerative disease • Genetics’ role greater when younger onset • CO poisoning, rural residence, pesticide or herbicide exposure, MPTP, encephalitis

  5. Nigrostriatal Dopaminergic Neurons Striatum Substantia nigra

  6. Substantia nigra, Normal Substantia nigra, PD

  7. CARDINAL FEATURES OF PARKINSON’S DISEASE • TRAP (any combination) • Tremor • Rigidity • Akinesia/Bradykinesia • Postural instability • Onset usually asymmetric • Diagnosis clinical

  8. TREMOR OF PARKINSON’S • Rest, 3-6 Hz, pill-rolling • Emotional stress may exacerbate • Inhibition by movement or sleep • Absent in ~20%

  9. BRADYKINESIA • Slowed voluntary movements • Less arm swing when walking • Reduced facial expression, less blinking • Identify by rapid alternating movements during examination

  10. OTHER FINDINGS • Facial and scalp seborrhea • Myerson’s sign • Drooling • Hypophonia, micrographia • Gait: shuffling, less arm swing, flexed, trouble starting and stopping • Cognitive decline • Normal: strength, DTR, Babinski

  11. DIFFERENTIAL DIAGNOSIS • Depression – facial expression, activity level • Drug-induced – onset usually symmetric • Essential tremor – possibly FH+ • Shy-Drager – parkinsonism + autonomic insufficiency + other signs • PSP • Lewy Body Dementia – parkinsonism, fluctuating cognition, psychosis

  12. TREATMENT • Successful levodopa trial makes diagnosis more likely • Drug aim: restore DA/ACh balance in striatum • No drugs convincingly slow progression • Wait to start drugs until bothersome symptoms or functional impairments

  13. DRUG TREATMENT • Important to individualize • Each patient’s tolerance for side effects? • When is need for mobility greatest?

  14. DRUG TREATMENT • Amantadine – for mild symptoms, risk of confusion and mood problems in elders • Anticholinergics • Benztropine, trihexyphenidyl • Confusion… • Agitation and restlessness… • Urinary retention…

  15. LEVODOPA • Converted by body to DA • Most effective drug • Combined with carbidopa to inhibit breakdown outside the brain (less nausea, hypotension, arrhythmias) • Sinemet (25/100) start one tid, increase gradually as needed • Controlled-release can reduce fluctuations

  16. LEVODOPA, cont’d • Amino acids compete for absorption • Take on empty stomach, or soda crackers • Last meal of day has most protein • Contraindications: psychosis, narrow-angle glaucoma, MAO-A inhibitors • Doesn’t help: autonomic dysfunction, postural instability, dementia, speaking and swallowing

  17. DOPAMINE AGONISTS • Fewer dyskinesias than levodopa • Approved as monotherapy, or as adjunct to levodopa • Adjunctive therapy  reduce levodopa  fewer dyskinesias, motor fluctuations • Many adverse effects; patients with cognitive impairment may tolerate levodopa better

  18. LEVODOPA VS. DA AGONIST • DA agonist • Perhaps worse motor performance • But less risk of motor complications • Greater odds of adverse drug effects

  19. DA AGONISTS, cont’d • Newer: pramipexole and ropinirole • Older (ergot): bromocriptine and pergolide • Slow dose titration to minimize adverse effects • Fatigue, sleepiness, nausea, dyskinesias, confusion, edema, orthostatic changes, dizziness, flushing and diaphoresis

  20. COMT INHIBITORS • Inhibit Catechol O-Methyl Transferase • Reduce breakdown of levodopa • Smoother blood levels, reduced response fluctuations • Tolcapone – rare fulminant liver failure, avoid in liver disease, monitor LFTs • Entacapone – LFTs not necessary • Watch for diarrhea; reduce Sinemet dose 1/3

  21. SURGICAL TREATMENTS • Ablation (eg, pallidotomy) or DBS • IDEAL CANDIDATE: cognitively intact, responds to dopaminergic drugs but progressive motor symptoms, can withstand procedure • Neurologist evaluation

  22. OTHER TREATMENTS • Physical Therapy – gait training, strength exercises, assistive devices • Improves mood, strength, flexibility, mobility • Front-wheel walkers typically best • Occupational Therapy – techniques and devices for eating, bathing, etc. • Speech Therapy – speaking, swallowing

  23. GEROPSYCHIATRIC COMPLICATIONS IN PD • Psychosis usually due to drug adverse effect • Try reduce dopaminergic dose • Quetiapine, olanzapine, risperidone may help • Clozapine most effective, risk of agranulocytosis • Dementia • Late development, up to ~30% • If earlier, consider Lewy Body Dementia • Depression – in up to ~40%

  24. GASTROINTESTINAL COMPLICATIONS • Dysphagia • Primarily oropharyngeal • Cause of drooling • Choking, coughing, aspiration • Treat: speech therapy

  25. GI COMPLICATIONS, cont’d • Constipation • Slowed colonic transport • Abundant fluids with high-fiber diet • Stool softeners, senna or sorbitol • Avoid anticholinergic medications • Periodic enemas, disimpaction may be needed

  26. Post-test question one Consider the case of a 78-year-old man with advanced Parkinson's disease who consults you for problems with worsening dyskinesias and excessive drooling. On physical examination you find he has rigidity in both upper extremities, more pronounced on the right, and he also has a pronounced pill-rolling tremor in his right hand. He shows very little spontaneous movement, and his face is expressionless, with rare blinking. On sternal nudge he steps back three steps and almost falls. Which of the following is NOT considered a cardinal feature of his parkinson?s disease? • Rigidity • Dyskinesias • Tremor • Bradykinesia • Postural instability

  27. Correct Answer:    Dyskinesias Feedback: The answer is (b) Dyskinesias. The other four are part of the cardinal tetrad of Parkinson's disease, which can be remembered using the "TRAP" mnemonic: T for tremor, R for rigidity, A for akinesia or bradykinesia, and P for postural instability. Let's move on to a second question about this patient

  28. Post-test question 2 The best way to treat excessive drooling in a patient with Parkinson's disease is with an anticholinergic agent such as trihexyphenidyl. • True • False

  29. Correct Answer: False • Feedback:As you probably surmised this is false. The drooling in Parkinson's patients results from improper handling of saliva in the oral cavity, not from excess production. This patient may benefit from referral to a speech pathologist. Use of an anticholinergic agent may precipitate confusion, urinary retention, visual complaints, or constipation. End

More Related